Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse...

Area of Science:

• Genomics
• Oncology
• Hematology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma.
• Current treatments yield long-term survival in about 60% of patients.
• Biologic markers may improve prognostic discrimination beyond the International Prognostic Index.

Purpose of the Study:

• To investigate DNA copy number changes in DLBCL patients with poor prognosis.
• To correlate these genomic alterations with treatment response and survival outcomes.

Main Methods:

• Array comparative genomic hybridization (array-CGH) was used to analyze DNA copy number changes.
• The study included 40 DLBCL patients treated uniformly with dose-escalated CHOP and stem cell transplantation.
• Analysis included univariate and multivariate assessments of genomic changes, age, and survival.

Main Results:

• A total of 722 copy number changes were observed, with a predominance of gains.
• Gains on 2p16 were associated with treatment failure after escalated CHOP therapy.
• Losses on 17p13 (TP53) and 10q23.31 (PTEN), along with advanced age, correlated with poor response and survival.

Conclusions:

• Array-CGH identified common copy number alterations in DLBCL.
• Specific genomic regions, including 2p16 gains and 17p13/10q23.31 losses, are associated with patient outcomes.
• These findings highlight the prognostic significance of genomic instability in DLBCL.